Seqens Seqens

X
[{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Effects of Dipyridamole on COVID-19 Patients With Coagulation Dysfunction 2 Coagulation Dysfunction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000142

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Zhongnan Hospital of Wuhan University

            Contact Supplier
            • Development Update
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            Details:

            HCoV-19 59 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, 60 suppressing hypercoagulability and enhancing immune recovery.

            Lead Product(s): Dipyridamole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY